DIFFERIN Drug Patent Profile

Which patents cover Differin, and when can generic versions of Differin launch?

Differin is a drug marketed by Galderma Labs Lp and is included in five NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in twelve countries.

The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the adapalene profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Differin

A generic version of DIFFERIN was approved as adapalene by P AND L on June 2^nd, 2010.

Summary for DIFFERIN

International Patents:	17
US Patents:	3
Applicants:	1
NDAs:	5
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	22
Patent Applications:	5,268
Drug Prices:	Drug price information for DIFFERIN
Drug Sales Revenues:	Drug sales revenues for DIFFERIN
What excipients (inactive ingredients) are in DIFFERIN?	DIFFERIN excipients list
DailyMed Link:	DIFFERIN at DailyMed

See drug prices for DIFFERIN

See drug sales revenues for DIFFERIN

Recent Clinical Trials for DIFFERIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	Early Phase 1
Bausch Health Americas, Inc.	Early Phase 1
Aurobindo Pharma Ltd	Phase 3

See all DIFFERIN clinical trials

Pharmacology for DIFFERIN

Drug Class

Retinoid

Paragraph IV (Patent) Challenges for DIFFERIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DIFFERIN	Topical Gel	adapalene	0.30%	021753	1	2009-09-15

US Patents and Regulatory Information for DIFFERIN

DIFFERIN is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	DIFFERIN	adapalene	CREAM;TOPICAL	020748-001	May 26, 2000	AB	RX	Yes	Yes
Galderma Labs Lp	DIFFERIN	adapalene	SOLUTION;TOPICAL	020338-001	May 31, 1996		DISCN	Yes	No
Galderma Labs Lp	DIFFERIN	adapalene	LOTION;TOPICAL	022502-001	Mar 17, 2010		DISCN	Yes	No	7,998,467		Y

Expired US Patents for DIFFERIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	021753-001	Jun 19, 2007	7,838,558
Galderma Labs Lp	DIFFERIN	adapalene	GEL;TOPICAL	021753-001	Jun 19, 2007	4,717,720
Galderma Labs Lp	DIFFERIN	adapalene	CREAM;TOPICAL	020748-001	May 26, 2000	4,717,720

International Patents for DIFFERIN

See the table below for patents covering DIFFERIN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1532974	Composition comprenant de l'acide 6-[3-(1-adamantyl)-4-méthoxyphényl]-2-naphthanoique pour le traitement de troubles dermatologiques (Composition comprising 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders)
China	104013540	Composition comprising at least one naphthoic acid derivative and at least one compound of polyurethane polymer type or derivatives thereof, preparation processes therefor and uses thereof
Japan	2012184258	COMPOSITION CONTAINING AT LEAST ONE DERIVATIVE OF NAPHTHOIC ACID AND AT LEAST ONE POLYURETHANE POLYMER TYPE COMPOUND OR DERIVATIVE THEREOF, PREPARATION METHOD, AND USE OF THE SAME

Supplementary Protection Certificates for DIFFERIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0199636	300209	Netherlands		300209, 20060411, EXPIRES: 20070702
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369	132008901685368	Italy		PRODUCT NAME: ADAPALENE E BENZOILE PEROSSIDO(EPIDUO); AUTHORISATION NUMBER(S) AND DATE(S): 40440, 20071218;DA 038261018/M A 038261057/M, 20080618

Market Dynamics and Financial Trajectory for Differin (Adapalene)

Last updated: December 28, 2025

Summary

Differin (adapalene) is a topical retinoid primarily used for the treatment of acne vulgaris. Originally launched as a prescription medication, it was later approved for over-the-counter (OTC) availability, significantly expanding its consumer base. This article analyzes the current market landscape, key drivers, competitive positioning, regulatory developments, and financial trajectory of Differin, providing insights for stakeholders in the pharmaceutical and OTC sectors.

---

What Are the Fundamental Market Drivers for Differin?

1. Growing Prevalence of Acne Vulgaris

• Global Incidence: Acne affects approximately 85% of adolescents and young adults worldwide (1).
• Market Segmentation: Predominantly targeting teenagers aged 12-24, with growing awareness among adults (2).
• Implication: A substantial, expanding patient base fuels market demand.

2. Transition from Prescription to OTC Access

• FDA Approval: In May 2016, the FDA approved Differin Gel 0.1% for OTC sale in the U.S., a first for a prescription-strength retinoid (3).
• Market Expansion: This regulatory shift removed barriers to access, increasing consumer uptake.
• Impact on Sales: OTC inclusion significantly boosts sales volume, especially through broader retail channels.

3. Consumer Preference for Acne Products

• Preference Shift: A trend toward self-medication and OTC treatments for mild to moderate acne (4).
• Brand Recognition: Differin's established efficacy and dermatologist reputation support consumer trust.

4. Competitive Landscape

Competitors	Key Attributes	Market Share	Notes
Adapalene-based Products	Differin, Altreno (gel and cream variants)	~55%	Leading within retinoid segment
Other OTC Acne Treatments	Benzoyl peroxide, salicylic acid, sulfur	Remaining	Compete mainly on price and formulation variety

5. Innovation and Pipeline Activity

• Extended Indications: Ongoing research into combination therapies and new formulations (e.g., low-dose formulations).
• Emerging Technologies: Integration with digital health tools for adherence and monitoring.

---

How Has Differin’s Regulatory and Market Environment Evolved?

Regulatory Milestones

Year	Event	Implication
2016	FDA approves OTC sales of Differin Gel 0.1%	Market expansion through OTC channels
2019	Approval of Differin Adaptel (adapalene 0.1%) for other skin conditions in Europe	Diversification potential
2021	Introduction of Differin Gel in key emerging markets (e.g., Southeast Asia, LATAM)	Geographic growth

Market Penetration Strategies

• Retail Partnerships: Major pharmacies, big-box retailers, and e-commerce platforms.
• Advertising Campaigns: Targeted social media and dermatologist endorsements.
• Education: Emphasizing safety profile and efficacy of OTC differentiations.

---

What Are the Key Financial Trends and Metrics?

Revenue Growth

Year	Revenue (USD millions)	Growth Rate	Notes
2016	N/A (launch year)	N/A	Introduction as prescription-only medication
2018	~$400	-	Post-OTC approval phase
2020	~$600	50% YoY increase	OTC dominance accelerates sales
2022	~$750	25% YoY growth	Continued market penetration

Sources: Company filings, industry reports (5).

Market Share and Competitive Revenue

• Differin's Share: Estimated capturing over 60% of the active OTC retinoid market in the U.S. (6).
• Pricing Dynamics: Average retail price ranges from $20–$25 for a 45g tube, with higher-margin sales driven by repeat purchases.

Profitability Metrics

Metric	2022 Estimate	Notes
Gross Margin	~60%	Due to premium positioning and branding
Operating Margin	15-20%	Benefits from economies of scale in OTC distribution
R&D Investments	~$50 million annually*	Focused on pipeline expansion and formulation innovation

Estimate based on typical pharmaceutical R&D budgets as a percentage of revenue (7).

---

How Does Differin Position Against Competitors?

Product Differentiation

Feature	Differin	Competitors
Active Ingredient	Adapalene (retinoid)	Benzoyl peroxide, salicylic acid
Prescription-to-OTC Transition	Yes	No
Efficacy for Acne	High	Variable
Safety Profile	Favorable, well-studied	Varies
Price Point	Moderate	Lower (generic counterparts)

Strengths and Weaknesses

Strengths	Weaknesses
Established efficacy; recognized dermatologist brand	Higher price point than some generics
Strong OTC market presence; direct-to-consumer marketing	Competition from newer formulations and combination therapies
High consumer trust and loyalty	Limited indications beyond mild-moderate acne

---

What Future Trends Could Shape Differin’s Market?

Product Innovation

• Combination Drugs: Adapalene combined with benzoyl peroxide or antibiotics.
• Formulations: Lower or higher strength options, alternative delivery systems (e.g., foam, patches).

Geographic Expansion

Region	Status	Opportunities
North America	Mature, OTC dominant	Maintenance growth, new indications
Europe	Approved; market growth	Market penetration through new formulations
Asia-Pacific & LATAM	Growing regulatory activities	Rapidly expanding markets, increasing acne prevalence

Digital and Personalized Medicine

• Mobile Apps for Adherence: Enhancing patient engagement.
• Teledermatology: Improving access and diagnosis accuracy.

Regulatory Landscape

• Potential for additional indications, e.g., psoriasis, rosacea, which could diversify revenue streams.
• Monitoring policies aimed at regulating OTC acne treatments to ensure safety and efficacy.

---

Key Challenges and Risks

Challenge	Risk Level	Mitigation Strategies
Competition from generics and brands	High	Continual innovation, marketing, and brand loyalty
Regulatory changes	Moderate	Active engagement with policymakers
Market saturation	Moderate	Geographic expansion, pipeline diversification
Consumer preference shifts	Low	Diversify product portfolio and formulation options

---

Conclusion: Differin’s Financial Trajectory Outlook

Differin’s transition to OTC status significantly transformed its market potential, fueling rapid revenue growth and capturing a leadership position in the acne treatment segment. The global acne market is projected to reach USD 9.2 billion by 2028 at a CAGR of 4.7% (8), with Differin expected to maintain a substantial share due to its established brand and expanding pipeline.

The company's future financial trajectory hinges on successful geographic expansion, pipeline innovation, and maintaining consumer trust amidst stiff competition. Strategic investments in R&D and digital health integrations will be crucial components propelling Differin’s growth in the evolving dermatological landscape.

---

Key Takeaways

• Market Expansion: OTC approval unlocked significant revenue potential; continued expansion into emerging markets is essential.
• Revenue Growth: Demonstrated strong growth averaging 25–50% annually since 2018.
• Competitive Edge: Differin’s efficacy, safety, and dermatologist endorsement support its dominant market position.
• Innovation & Pipeline: Future success depends on product diversification, combination therapies, and new formulations.
• Regulatory & Market Risks: Vigilance required to navigate evolving policies and competitive pressures.

---

FAQs

1. What factors led to Differin’s successful shift from prescription to OTC?

Regulatory approval by the FDA in 2016, combined with proven safety and efficacy, supported the OTC switch, enabling broader consumer access and leading to increased sales.

2. How does Differin compare financially with its main competitors?

Differin maintains a higher price point with stronger brand recognition, translating to higher margins compared to generics or less-established OTC acne treatments.

3. What are the main growth opportunities for Differin in the next five years?

Global market expansion, pipeline development for combination therapies, and technological integration via digital health tools present key opportunities.

4. What risks could impede Differin’s market growth?

Intensified competition, regulatory uncertainty, market saturation, or shifts in consumer preferences could impact growth trajectories.

5. How is Differin poised to differentiate itself from emerging acne treatments?

Through continuous innovation, strategic marketing, and expansion into new formulations and indications, Differin aims to retain its market leadership and adapt to evolving consumer needs.

---

References

1. Global Burden of Disease Study. Acne Prevalence Data. 2022.
2. American Academy of Dermatology. Acne Trends and Demographics. 2021.
3. FDA News Release. “FDA Approves First Over-the-Counter Acne Treatment”. May 2016.
4. MarketResearch.com. Consumer Trends in OTC Dermatology. 2022.
5. Company Annual Reports (2018-2022).
6. IQVIA Data. OTC Acne Market Share. 2022.
7. Pharmaceutical R&D Budget Reports. 2021.
8. Fortune Business Insights. Acne Market Size & Growth. 2022.

---